MedTrace Logo

A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

NCT05765279 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2023-03-13

No results posted yet for this study

Summary

An Investigator-initiated, Randomized, Single-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of SARS-Cov-2 Post Exposure Prophylaxis and Safety of HH-120 nasal spray

Conditions

Interventions

DRUG

HH-120 nasal spray 1

HH-120 nasal spray 5 times daily for 3 consecutive days

DRUG

HH-120 nasal spray 2

HH-120 nasal spray 8 times daily for 3 consecutive days

DRUG

Placebo Comparator 1

Placebo nasal spray 5 times daily for 3 consecutive days

DRUG

Placebo Comparator 2

Placebo nasal spray 8 times daily for 3 consecutive days

Sponsors & Collaborators

  • Beijing Ditan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-20
Primary Completion
2022-12-06
Completion
2022-12-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05765279 on ClinicalTrials.gov